Thalidomide / Dexamethasone (TD) Vs. Bortezomib (Velcade)a/Thalidomide / Dexamethasone (VTD) Vs. VBMCP/VBAD/Velcadea as Induction Regimens Prior Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma (MM): Results of a Phase III PETHEMA/GEM Trial.
Laura Rosiñol(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Joan Bladé(Hospital Clínic de Barcelona), Juan José Lahuerta(Research Institute Hospital 12 de Octubre), Dolores Hernández‐Maraver(Centre Hospitalier Universitaire de Grenoble), María‐Victoria Mateos(Hospital Clínico San Carlos), Javier de la Rubia(Universitat de València), Joaquín Martínez‐López(Hospital Universitario 12 De Octubre), Adrían Alegre(Hospital Universitario de La Princesa), J.F F San Miguel(Complejo Hospitalario de Salamanca), Juan Besalduch(Hospital Universitario Son Dureta), Albert Oriol(Institut Català d'Oncologia), Miguel‐Teodoro Hernández(Hospital Universitario de Canarias), María José Terol(Hospital Clínico Universitario de Valencia), Ma Asuncion Echebeste(Biogipuzkoa Health Research Institute), Anna Sureda(Institut d'Investigació Biomédica de Bellvitge), Luis Palomera(BioCruces Health research Institute), José García‐Laraña, M. Teresa Cibeira(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Joaquín Diaz‐Mediavilla(Hospital Clínico San Carlos), Felipe de Arriba(Hospital General Universitario Morales Meseguer)
Cited by 45
Related Papers
International Staging System for Multiple Myeloma
|Journal of Clinical Oncology|2005|2.9k
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
|New England Journal of Medicine|2021|1.6k
CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION
|British Journal of Haematology|1998|1.5k